ENVERIC BIOSCIENCES INC

ENVBNASDAQ

🏆 #3828 by market capEarnings Aug 17US Equity

$1.55▲ $0.01 (+0.65%)

Live

1h—

24h▲ 0.7%

7d—

14d—

30d—

1y—

🏦Market Cap

$6M

Small Cap

📈Revenue Growth (YoY)

-7.2%

Declining

📊Gross Margin

20.4%

Moderate

💵FCF Margin

0.4%

Thin

⚖️P/S Ratio

0.1x

Cheap

Otter Score

Weak

No chart data available for ENVB.

Trading Snapshot

Day Range: $1.53 – $1.57
52-Week Range: $1.25 – $17.64
Volume: $1.92B
Avg Volume: $1.98B
Shares Outstanding: 3.7M
Next Earnings: Sep 6, 2026

Fundamentals Snapshot

Annual Revenue: $40M
Last Q Revenue: $9M
P/E Ratio: —
P/S Ratio: 0.1x
EPS (TTM): $-22.04
Dividend Yield: —

Why Investors Own ENVB

✓High-growth profile — revenue up +35.1% YoY with expanding US Equity exposure.
✓Healthy economics — 39% gross margin and 20% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$40M▲ +31.7% YoY

Gross Margin (TTM)

38.5%▲ +0.6% YoY

Operating Income (TTM)

$14M▲ +31.7% YoY

Free Cash Flow (TTM)

$8M▲ +31.7% YoY

About ENVERIC BIOSCIENCES INC

Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.

🦦